Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC)
Yoo, C. Finn, R. S. Mpen, H. Kelley, R. K. Vogel, A. Furuse, J. Ren, Z. G. Yau, T. Chan, S. L. Ozaka, M.
Yoo, C.
Finn, R. S.
Mpen, H.
Kelley, R. K.
Vogel, A.
Furuse, J.
Ren, Z. G.
Yau, T.
Chan, S. L.
Ozaka, M.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Yoo C, Finn RS, Mpen H, Kelley RK, Vogel A, Furuse J, et al. Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772000829.